Vol. 5 No. 10 (2025)
Reimbursement Reviews

Dostarlimab (Jemperli)

decorative image of the issue cover

Published October 6, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses dostarlimab (Jemperli), 50 mg/mL, solution for IV infusion in 500 mg/10 ml vial, 500mg Q3W for 6 cycles followed by 1000mg Q6W, IV infusion.
  • Indication: Jemperli is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or first recurrent endometrial cancer who are candidates for systemic therapy.